KORU Medical reports preliminary Q4 revenue growth of 23%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
KORU Medical Systems Reports Preliminary Q4 and Full Year 2025 Results; Achieves Record Revenue and Full Year Positive Operating Cash Flow
January 12, 2026 8:00 AM ESTMAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems (NASDAQ: KRMD) (KORU Medical or the Company), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2025.
Financial Results (unaudited)
Preliminary, unaudited fourth quarter 2025 net revenues expected to be $10.9 million, representing growth of 23% over the prior year period Preliminary, unaudited full year 2025 net revenues expected to be $41.1 million, representing growth of 22% over... More